Current Report Filing (8-k)
April 17 2018 - 6:08AM
Edgar (US Regulatory)
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): April 12, 2018
Atossa
Genetics Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35610
|
|
26-4753208
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
107
Spring Street
Seattle,
Washington
|
|
98104
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (206) 325-6086
Not
Applicable
Former name or former address, if changed since last report
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission
of Matters to a Vote of Security Holders
On
April 12, 2018, the Company held its 2018 Annual Meeting of Stockholders (the “
Annual Meeting
”). The following
items of business were considered and voted upon at the Annual Meeting: (1) the election of two Class III directors named in the
proxy statement related to the Annual Meeting; (2) the ratification of the selection of BDO USA LLP as our independent registered
public accounting firm for the fiscal year ending December 31, 2018; (3) the approval to increase authorized shares under Atossa
Genetics 2010 Stock Option and Incentive Plan by 6,000,000 shares; (4) approval of an amendment (in the event it is deemed by
the Atossa’s Board of Directors to be advisable) to Atossa’s certificate of incorporation to effect a reverse stock
split of the issued and outstanding shares of Atossa’s common stock at a ratio within the range of 1:3 up to a split of
1:15, as determined by the Atossa’s Board of Directors; (5) the approval of an amendment to the certificate of incorporation
to increase the number of authorized shares of common stock by 100,000,000 shares; (6) to conduct an advisory (non-binding) vote
on the compensation of our named executive officers as described in the proxy statement related to the Annual Meeting; (7) an
advisory (non-binding) vote on the frequency of future advisory votes on executive compensation; and (8) the transaction of any
other business that may properly come before the meeting or any adjournment thereof.
The
number of shares of common stock entitled to vote at the Annual Meeting was 31,822,741. The number of shares of common stock present
or represented by valid proxy at the annual meeting was 23,073,057. All proposals passed except proposals 4 and 5. The number
of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the
Annual Meeting, other than proposals 4 and 5, are set forth below:
(i)
|
Election of two Class III Directors
|
The
stockholders elected two Class III directors as set forth below:
Nominee
|
Votes
For
|
Votes
Withheld
|
Broker
Non-Votes
|
Shu-Chih
Chen
|
6,455,645
|
1,320,215
|
15,297,197
|
Lawrence
Remmel
|
6,449,833
|
1,326,027
|
15,297,197
|
(ii)
|
Ratification
of Auditors
|
The
stockholders ratified the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for
the fiscal year ending December 31, 2018 as set forth below:
Votes
For
|
Votes
Against
|
Abstain
|
Broker
Non-Votes
|
20,425,441
|
1,097,055
|
1,550,561
|
0
|
(iii)
|
Increase Authorized
Shares under Option Plan
|
The
stockholders approved an increase of 6,000,000 shares to the option plan as follows:
Votes
For
|
Votes
Against
|
Abstain
|
Broker
Non-Votes
|
5,257,123
|
2,349,198
|
169,539
|
15,297,197
|
(iv)
|
Non-binding Vote
on Executive Compensation
|
The
stockholders approved an advisory non-binding vote on executive compensation as follows:
Votes
For
|
Votes
Against
|
Abstain
|
Broker
Non-Votes
|
4,828,179
|
2,717,507
|
230,174
|
15,297,197
|
(v)
|
Non-binding Vote
on Frequency of Say-on-Pay
|
The
stockholders approved an advisory non-binding vote on the frequency of the vote on executive compensation as follows:
Annual
|
Biennial
|
Triennial
|
Abstain
|
Broker
Non-Votes
|
5,438,719
|
1,379,973
|
371,487
|
585,681
|
15,297,197
|
At
the time of the 2018 Annual Meeting, there were insufficient votes to pass proposal 4 to authorize the reverse split in a range
of 1:3 to 1:15, and proposal 5 to increase the authorized shares of common stock by 100,000,000 shares. Given the importance of
these proposals, the meeting was adjourned to allow additional time for voting on these proposals. The meeting will reconvene
at 1 p.m. PDT on April 19, 2018 at 107 Spring Street, Seattle, Washington 98104. During the period of adjournment the Company
will continue to accept stockholder votes on these proposals.
*
* *
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: April 16,
2018
|
Atossa Genetics Inc.
|
|
|
|
|
|
By:
|
/s/
Kyle Guse
|
|
|
|
Kyle Guse
|
|
|
|
Chief Financial Officer, General Counsel and Secretary
|
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024